J&J Medical Device Revenue Up, But Cypher Sales Are Still A Drag
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's device revenue growth is still hindered by declining sales of the Cypher sirolimus-eluting coronary stent, the company reported during its first-quarter earnings call April 17